A groundbreaking development in global healthcare is set to make HIV prevention more affordable and accessible. Starting in 2027, a new HIV-prevention drug will be available at just $40 per year, significantly lowering the cost of treatment and prevention for millions worldwide.
Health experts say the move could transform efforts to curb the spread of HIV, especially in low- and middle-income countries where affordability has been a major barrier. The drug, designed for long-term use, is expected to drastically reduce new infections and support global goals of ending the HIV epidemic.
Public health organizations and NGOs have welcomed the announcement, noting that accessibility and affordability remain the cornerstones of successful prevention campaigns. The reduced cost is also expected to ease financial pressure on governments and international aid programs funding large-scale distribution.
